GB201415250D0 - Compound and method - Google Patents

Compound and method

Info

Publication number
GB201415250D0
GB201415250D0 GBGB1415250.8A GB201415250A GB201415250D0 GB 201415250 D0 GB201415250 D0 GB 201415250D0 GB 201415250 A GB201415250 A GB 201415250A GB 201415250 D0 GB201415250 D0 GB 201415250D0
Authority
GB
United Kingdom
Prior art keywords
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1415250.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PCI Biotech AS
Original Assignee
PCI Biotech AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PCI Biotech AS filed Critical PCI Biotech AS
Priority to GBGB1415250.8A priority Critical patent/GB201415250D0/en
Publication of GB201415250D0 publication Critical patent/GB201415250D0/en
Priority to PCT/EP2015/069793 priority patent/WO2016030528A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB1415250.8A 2014-08-28 2014-08-28 Compound and method Ceased GB201415250D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1415250.8A GB201415250D0 (en) 2014-08-28 2014-08-28 Compound and method
PCT/EP2015/069793 WO2016030528A1 (en) 2014-08-28 2015-08-28 Compound and method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1415250.8A GB201415250D0 (en) 2014-08-28 2014-08-28 Compound and method

Publications (1)

Publication Number Publication Date
GB201415250D0 true GB201415250D0 (en) 2014-10-15

Family

ID=51752277

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1415250.8A Ceased GB201415250D0 (en) 2014-08-28 2014-08-28 Compound and method

Country Status (2)

Country Link
GB (1) GB201415250D0 (en)
WO (1) WO2016030528A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102646264B1 (en) * 2018-09-27 2024-03-11 주식회사 엘지화학 Antibacterial polymer composition
RU2720799C1 (en) * 2019-07-03 2020-05-13 Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" Method of determining fractional composition of sulphonated aluminum phthalocyanine
GB202115451D0 (en) * 2021-10-27 2021-12-08 Pci Biotech As Method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9905911D0 (en) * 1999-03-15 1999-05-05 Photocure As Method
US7223600B2 (en) * 2000-11-29 2007-05-29 The Norwegian Radium Hospital Research Foundation Photochemical internalization for delivery of molecules into the cytosol

Also Published As

Publication number Publication date
WO2016030528A1 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
FI3215147T3 (en) Neuro-attenuating norketamine compounds and methods
GB201406151D0 (en) Method
GB201409558D0 (en) Method
GB201406155D0 (en) Method
GB201408119D0 (en) Method
PT2980420T (en) Panel-insert assembly and method
GB201403470D0 (en) Method
HK1243342A1 (en) Compounds and methods
GB201410022D0 (en) Method
GB201503776D0 (en) Compound and method
GB201410101D0 (en) Method
GB201415250D0 (en) Compound and method
GB201411500D0 (en) Method
GB201409128D0 (en) Method
HK1220676A1 (en) Arrangement and method
EP3185901C0 (en) Compound and method
GB201409234D0 (en) Method
GB201409101D0 (en) Method
GB201416082D0 (en) Method and uses
GB201408649D0 (en) Method
GB201420773D0 (en) Compound and method
GB201415247D0 (en) Compound and method
GB201415254D0 (en) Compound and method
GB201406598D0 (en) Compound and method
GB201406599D0 (en) Compound and method

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)